Skip to main content
OpenTrials
Completed

NCT Number: NCT04324450

Memory Neuroimaging in Children, Adolescents and Young Adults Following Pediatric Cancer

Brain tumours are the leading cause of cancer-related death and morbidity in children, adolescents and young adults. The brain is also one of the most sensitive organs to treatments used in pediatric oncology, even for cancers not related to the central nervous system. Therapeutic index is therefore a major issue in pediatric neuro-oncology. The efficacy of the therapy as well as its toxicity are difficult to measure using standard tests. In order to optimize therapies that could have an impact on the brain, and consequently on the quality of life of patients, it becomes crucial to optimize the means of evaluation.

Few studies to date have focused on the various components of memory impacted following treatment of a posterior fossa tumour. However, supra-tentorial structures such as the hippocampus, which have long been described for their role in memory, are either partially irradiated (irradiated in their lower part due to their proximity to the target volume during irradiation of the posterior fossa) or completely irradiated (e.g. included in the prophylactic irradiation of medulloblastoma prior to dose supplementation in the posterior fossa). On the other hand, the cerebellum plays a central role in learning and procedural memory involved in motor and cognitive learning, as it enables automation and procedural retention such as reading (automation of the grapho-phonemic conversion procedure) or arithmetic (mental arithmetic).

IMPALA study is aimed at investigating the impact of different irradiation doses received by children treated with radiotherapy on cognitive functions related to the hippocampus and to the cerebellum.

This exploratory study will thus provide elements enabling a better limitation of radiotherapy doses on regions linked to the development of cognition and memory. The project brings together researchers and clinicians with complementary expertise in oncology, neurology and imaging in both children and adults. This study will also provide a better understanding of the role of the cerebellum in memory and executive functions, and develop a method that can then be used in a prospective longitudinal multicentre form.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

ToNIC / UMR1214

Toulouse, 31024, France

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

FOR ALL PARTICIPANTS

  • Affiliation to or beneficiary of a social security scheme
  • French mother tongue
  • Sufficient visual, auditory (hearing aids permitted), speaking and writing skills for proper performance of neuropsychological tests
  • Written informed consent of the adult participant, or of the representatives of parental authority, if applicable

FOR IRRADIATED PATIENTS

  • Patient treated before 18 years old
  • Patient considered cured after irradiation of a brain tumour (complete clinical and iconographic response at 5 years after the end of radiotherapy).
  • Patient who has received localized brain irradiation or craniospinal irradiation for a brain tumour whose treatment includes first-line radiotherapy (ependymomas, medulloblastomas, malignant germinal tumours)
  • Patient who received 54 or 59.4 Gy in a localized part of the posterior fossa or supra-tentorial brain; or patients who received 54 Gy over all or part of the posterior fossa and prophylactic irradiation of the entire brain

FOR PATIENTS TREATED BY SURGERY AND/OR CHEMOTHERAPY

  • Patients resected from a posterior fossa tumour without radiotherapy (i.e., brain tumours whose treatment does not include first-line radiotherapy: low-grade gliomas including pilocytic astrocytomas)
  • Patient treated before 18 years old
  • Patient considered cured at 5 years after the end of treatment

Exclusion criteria

FOR ALL PARTICIPANTS

  • Individual under legal protection of adults (judicial safeguard, guardianship, curatorship, institutionalized, or under a mandate for future protection)
  • Severe ataxia
  • Individual who participated in another research study that included treatment within the previous 3 years
  • Individual with a contraindication to MRI (i.e. in particular, cardiac pacemaker or defibrillator carriers, implanted equipment activated by an electrical, magnetic or mechanical system, carriers of haemostatic clips on intracerebral aneurysms, carriers of orthopaedic implants, claustrophobic)

FOR HEALTHY VOLUNTEERS

  • Known neurological or psychiatric history
  • History of learning disability or neurodevelopmental disorder follow-up
  • Patients undergoing psychotropic treatment (methylphenidate, antidepressants, etc.).

Treatment and study plan

MRI

Device

The MRI protocol is composed of:

  • T1-weighted anatomical sequences
  • DTI sequences
  • resting functional MRI
  • 3D MR spectroscopic imaging

Cognitive assessment

Behavioral

Battery of neuropsychological tests

Primary outcomes

  1. Structural characteristics of declarative memory neuronal substrate: volume of the hippocampus

    Time frame: Day 1

    Volume of the hippocampus obtained from T1-weighted anatomical

  2. Structural characteristics of declarative memory neuronal substrate: cortical thickness of the hippocampus

    Time frame: Day 1

    Cortical thickness of the hippocampus obtained from T1-weighted anatomical

  3. Structural characteristics of declarative memory neuronal substrate: Microstructural integrity of the hippocampus

    Time frame: Day 1

    Microstructural integrity of the hippocampus obtained from Diffusion Tensor Imaging (DTI) sequences used to calculate the fraction of anisotropy and the mean diffusion sequences

  4. Episodic memory performance

    Time frame: Day 2

    Episodic memory performance of the participants in the different groups when evaluating episodic declarative memory, assessed with Children's Memory Scale in participants under 16 years old and with Wechsler Memory Scale MEM-III in participants over 16 years old (Day 2)

Secondary outcomes

  1. Declarative episodic memory assessment scores

    Time frame: Day 2

    Scores obtained at memory clinical scale for children

  2. Declarative semantic memory assessment scores

    Time frame: Day 2

    Scores obtained at Wechsler Intelligence Scale for Children

  3. Procedural memory assessment scores

    Time frame: Day 2

    Scores obtained at Serial Reaction Time Task

  4. Short-term auditive memory assessment scores

    Time frame: Day 2

    Scores obtained at Wechsler Intelligence Scale for Children

  5. Short-term visual memory assessment scores

    Time frame: Day 2

    Scores obtained at Wechsler Memory Scale

  6. Intellectual capacities assessment scores

    Time frame: Day 2

    Scores obtained at Wechsler Intelligence Scale for Children

  7. Language assessment scores

    Time frame: Day 2

    Scores obtained at Peabody Picture Vocabulary Test

  8. Motor functions assessment scores

    Time frame: Day 2

    Scores obtained at Purdue Pegboard Test

  9. Executive functions assessment scores

    Time frame: Day 2

    Scores obtained at TMT A and B, Stroop Test and Wisconsin Card Sorting Test

  10. Attentional capacities assessment scores

    Time frame: Day 2

    Scores obtained at Test of Attentional Performance 2.3.1

  11. Cerebellar volume

    Time frame: Day 1

    Cerebellar volume obtained from T1-weighted anatomical sequences

  12. Micro-structural integrity of the cerebellum

    Time frame: Day 1

    Micro-structural integrity of the cerebellum achieved by using DTI sequences to calculate the fraction of anisotropy and average diffusivity

  13. Cerebral blood volume obtained from brain perfusion imaging

    Time frame: Day 1

    Cerebral blood volume obtained from brain perfusion imaging

  14. Post-therapeutic hypoxia

    Time frame: Day 1

    Post-therapeutic hypoxia as measured by magnetic resonance spectrometry of the hippocampus and cerebellum

  15. Neuronal density

    Time frame: Day 1

    Neuronal density as measured by magnetic resonance spectrometry of the hippocampus and cerebellum

  16. Functional connectivity index

    Time frame: Day 1

    Functional connectivity index, obtained via resting functional MRI.

  17. Age at the time of treatment

    Time frame: Day 1

    Age at the time of treatment from the patients' medical records

  18. Radiotherapy doses

    Time frame: Day 1

    Radiotherapy doses received in the cerebellum, in the hippocampus, and in the whole brain from the patients' medical records

  19. Cerebellum and hippocampus Normal Tissue Complication Probability

    Time frame: Day 1

    Cerebellum and hippocampus Normal Tissue Complication Probability (NTCP)

Sponsors and collaborators

Lead sponsor

Institut National de la Santé Et de la Recherche Médicale, France

Other Gov

Registry information

Acronym: IMPALA

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Mar 27, 2020
Registry last updated
Sep 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.